Teva Pharmaceutical Industries Ltd. TEVA announces today that the U.S.
Food and Drug Administration has granted approval of the generic equivalent to
TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to
an agreement with Novartis NVS on this product, Teva expects to launch this
product in late November. Marketed by Novartis, TOBI^® had annual sales of
approximately $350 million in the United States, according to IMS data as of
June 30, 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in